Triamcinolone and its derivatives are synthetic glucocorticoids used as anti-inflammatory or immunosuppressive agents. Triamcinolone is commercially available in oral, parenteral, topical, and aerosol formulations. Triamcinolone decreases inflammation by inhibiting the release of leukocytic acid hydrolases, preventing macrophage accumulation at the site of infection, interfering with leukocyte adhesion to the capillary wall, reducing capillary membrane permeability (thereby reducing edema), reducing complement components, inhibiting histamine and kinin release, and interfering with the formation of scar tissue. Inhaled Triamcinolone is believed to reduce the immediate and late-phase allergic responses associated with chronic bronchial asthma. Triamcinolone was approved by the FDA in 1957.